Volume 23, Issue 3 (8-2021)                   yafte 2021, 23(3): 158-167 | Back to browse issues page

XML Persian Abstract Print

Department of Medical Microbiology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
Abstract:   (1981 Views)
Background: Today, drug-resistant strains of Acinetobacter baumannii are one of the opportunistic pathogens in the world. This study aimed to determine the antibiotic resistance pattern of clinical isolates of A. baumannii in Khorramabad hospitals (i.e., Shohaday Ashayer-Shahid Rahimi), Khorramabad, Iran.
Materials and Methods: This cross-sectional study was conducted on the clinical samples collected from patients hospitalized in the different wards of Khorramabad hospitals in 2015-16 and 2017-18. The clinical samples were identified as A. baumannii by microbiological culture and biochemical tests then confirmed by polymerase chain reaction. The susceptibility test of bacterial isolates to antibiotics was performed and the obtained data were analyzed by SPSS software (version 22) using the Chi-square test.
Results: According to the results of the antibiogram, among the 94 isolates of A. baumannii collected from the patients admitted to Khorramabad hospitals, 50%, 41.49%, and 8.51% of isolates were multiple-drug resistant, extensively drug-resistant, and non-multidrug resistance, respectively.
Conclusion: Due to the sensitivity of A. baumannii to polymyxin B and minocycline antibiotics, these antibiotics can be used, especially as a combination therapy, in the treatment of infections caused by this bacterium. Since the rate of multidrug resistance in Khorramabad hospitals was found to be 91.49%, it is necessary to pay attention to the criteria for controlling nosocomial infections.
Full-Text [PDF 292 kb]   (1232 Downloads)    
Type of Study: Research | Subject: میکروب شناسی
Received: 2021/03/27 | Accepted: 2021/05/16 | Published: 2021/09/5

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.